Published in Virol J on August 08, 2011
KASL clinical practice guidelines: management of chronic hepatitis B. Clin Mol Hepatol (2016) 1.07
Comparison of efficacy and safety of tenofovir and entecavir in chronic hepatitis B virus infection: a systematic review and meta-analysis. PLoS One (2014) 1.00
Antiviral treatment to prevent chronic hepatitis B or C-related hepatocellular carcinoma. World J Virol (2012) 0.96
Update on rescue therapies in patients with lamivudine-resistant chronic hepatitis B. Drug Des Devel Ther (2013) 0.87
Acute-on-chronic liver failure: Pathogenesis, prognostic factors and management. World J Gastroenterol (2015) 0.82
Binding sensitivity of adefovir to the polymerase from different genotypes of HBV: molecular modeling, docking and dynamics simulation studies. Acta Pharmacol Sin (2012) 0.80
Effects of telbivudine and entecavir for HBeAg-positive chronic hepatitis B: a meta-analysis. World J Gastroenterol (2012) 0.78
A case report of de novo hepatocellular carcinoma after living donor liver transplantation. World J Surg Oncol (2013) 0.78
Measures to reduce mother-to-child transmission of Hepatitis B virus in China: a meta-analysis. Dig Dis Sci (2013) 0.78
Entecavir Interacts with Influx Transporters hOAT1, hCNT2, hCNT3, but Not with hOCT2: The Potential for Renal Transporter-Mediated Cytotoxicity and Drug-Drug Interactions. Front Pharmacol (2016) 0.78
HIV/HBV coinfection in children and antiviral therapy. Expert Rev Anti Infect Ther (2013) 0.78
Long-term outcomes of two rescue therapies in lamivudine-refractory patients with chronic hepatitis B: combined lamivudine and adefovir, and 1-mg entecavir. Clin Mol Hepatol (2014) 0.77
Detection and analysis of resistance mutations of hepatitis B virus. Int J Clin Exp Med (2015) 0.75
LHBs can elevate the expression of MDR1 through HIF-1α in patients with CHB infection: a comparative proteomic study. Oncotarget (2017) 0.75
Efficacy of 3 years of adefovir monotherapy in chronic hepatitis B patients with lamivudine resistance. World J Hepatol (2012) 0.75
Interleukin-1 receptor antagonist expression is inversely associated with outcomes of hepatitis B-related acute-on-chronic liver failure. Exp Ther Med (2017) 0.75
Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials (1996) 64.38
Chronic hepatitis B: update 2009. Hepatology (2009) 16.08
Chronic hepatitis B. Hepatology (2007) 13.75
Hepatitis B virus infection--natural history and clinical consequences. N Engl J Med (2004) 10.91
Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA (2006) 10.58
Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology (2006) 6.67
Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med (2006) 5.65
Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology (2009) 4.00
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology (2006) 3.80
Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis (2003) 3.69
Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology (2007) 2.78
Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology (2008) 2.70
Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother (2004) 2.67
Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology (2007) 2.11
Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology (2007) 2.03
Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients. J Gastroenterol Hepatol (2008) 1.78
Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up. J Hepatol (2008) 1.76
Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology (2007) 1.72
Antiviral resistance and hepatitis B therapy. Hepatology (2009) 1.67
Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology (2008) 1.65
Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. J Hepatol (2008) 1.63
Lamivudine-resistant chronic hepatitis B: an observational study on adefovir in monotherapy or in combination with lamivudine. J Hepatol (2008) 1.60
Clinical relevance and public health significance of hepatitis B virus genomic variations. World J Gastroenterol (2009) 1.56
EASL Clinical Practice Guidelines. J Hepatol (2008) 1.53
Hepatitis B virus replication and liver disease progression: the impact of antiviral therapy. Antivir Ther (2006) 1.53
Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir. Hepatology (2009) 1.40
Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. J Hepatol (2006) 1.27
Meta-analysis: adefovir dipivoxil in combination with lamivudine in patients with lamivudine-resistant hepatitis B virus. Virol J (2009) 1.23
Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy. J Gastroenterol Hepatol (2010) 1.21
Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B. J Med Virol (2010) 1.18
Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta-analysis. J Viral Hepat (2009) 1.06
Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir. J Hepatol (2010) 1.04
Long-term nucleos(t)ide analogues therapy for adults with chronic hepatitis B reduces the risk of long-term complications: a meta-analysis. Virol J (2011) 1.01
Add-on adefovir is superior to a switch to entecavir as rescue therapy for Lamivudine-resistant chronic hepatitis B. Dig Dis Sci (2011) 0.93
Complex dynamics of hepatitis B virus resistance to adefovir. Hepatology (2009) 0.92
Unusual selection of rtA181V HBV mutants cross-resistant to adefovir following prolonged lamivudine monotherapy: report of two cases. Antivir Ther (2006) 0.87
[A study on the treatment of chronic hepatitis B with YMDD mutation]. Zhonghua Gan Zang Bing Za Zhi (2009) 0.78
Calcium/vitamin D supplementation and cardiovascular events. Circulation (2007) 6.63
Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial. Hepatology (2008) 2.13
ATP hydrolysis by mammalian RAD51 has a key role during homology-directed DNA repair. J Biol Chem (2002) 1.97
Sleep duration and risk of ischemic stroke in postmenopausal women. Stroke (2008) 1.80
Intra-nuclear trafficking of the BLM helicase to DNA damage-induced foci is regulated by SUMO modification. Hum Mol Genet (2005) 1.66
Functional analysis of promoter mutations in the ACTN4 and SYNPO genes in focal segmental glomerulosclerosis. Nephrol Dial Transplant (2009) 1.58
Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol (2009) 1.52
Cardiovascular risk in women with non-specific chest pain (from the Women's Health Initiative Hormone Trials). Am J Cardiol (2008) 1.46
Protein phosphatase 6 down-regulates TAK1 kinase activation in the IL-1 signaling pathway. J Biol Chem (2006) 1.37
Predicting progression of IgA nephropathy: new clinical progression risk score. PLoS One (2012) 1.30
Transcriptomic and genomic evolution under constant cold in Antarctic notothenioid fish. Proc Natl Acad Sci U S A (2008) 1.26
Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials. Nephrol Dial Transplant (2007) 1.24
Decreased Dicer expression elicits DNA damage and up-regulation of MICA and MICB. J Cell Biol (2008) 1.20
Diagnosis and treatment of polypoid lesions of the gallbladder: report of 194 cases. Hepatobiliary Pancreat Dis Int (2004) 1.20
Enhancement of canonical Wnt/β-catenin signaling activity by HCV core protein promotes cell growth of hepatocellular carcinoma cells. PLoS One (2011) 1.16
A randomized controlled phase IIb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients. PLoS One (2008) 1.14
The Arabidopsis D-type cyclin CYCD2;1 and the inhibitor ICK2/KRP2 modulate auxin-induced lateral root formation. Plant Cell (2011) 1.14
From procaspase-8 to caspase-8: revisiting structural functions of caspase-8. J Cell Physiol (2010) 1.12
Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis. Nephrol Dial Transplant (2011) 1.12
Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings. J Hepatol (2013) 1.12
[Long-term health-related quality of life in chronic hepatitis B patients]. Zhonghua Gan Zang Bing Za Zhi (2003) 1.08
Anxiolytic effect of wogonin, a benzodiazepine receptor ligand isolated from Scutellaria baicalensis Georgi. Biochem Pharmacol (2002) 1.08
Let-7: a regulator of the ERα signaling pathway in human breast tumors and breast cancer stem cells. Oncol Rep (2013) 1.07
Induction of MHC class I-related chain B (MICB) by 5-aza-2'-deoxycytidine. Biochem Biophys Res Commun (2008) 1.07
Down-regulation of Dicer in hepatocellular carcinoma. Med Oncol (2010) 1.06
Single nucleotide polymorphisms of the IL28B and sustained virologic response of patients with chronic hepatitis C to PEG-interferon/ribavirin therapy: A meta-analysis: Meta-analysis of IL28B. Hepat Mon (2011) 1.06
Live poultry market closure and control of avian influenza A(H7N9), Shanghai, China. Emerg Infect Dis (2014) 1.05
Coexistence of normotensive primary aldosteronism in two patients with Gitelman's syndrome and novel thiazide-sensitive Na-Cl cotransporter mutations. Eur J Endocrinol (2009) 1.04
The c-Abl-MST1 signaling pathway mediates oxidative stress-induced neuronal cell death. J Neurosci (2011) 1.03
A brassinolide-suppressed rice MADS-box transcription factor, OsMDP1, has a negative regulatory role in BR signaling. Plant J (2006) 1.03
Compressed sensing with wavelet domain dependencies for coronary MRI: a retrospective study. IEEE Trans Med Imaging (2011) 1.02
Fabrication of Porous TiO(2) Hollow Spheres and Their Application in Gas Sensing. Nanoscale Res Lett (2010) 1.02
Coiled versus straight peritoneal dialysis catheters: a randomized controlled trial and meta-analysis. Am J Kidney Dis (2011) 1.02
Long-term nucleos(t)ide analogues therapy for adults with chronic hepatitis B reduces the risk of long-term complications: a meta-analysis. Virol J (2011) 1.01
Sequencing of PCR amplified HBV DNA pre-c and c regions in the 2.2.15 cells and antiviral action by targeted antisense oligonucleotide directed against sequence. World J Gastroenterol (1998) 1.00
Sites in the fourth membrane-associated domain regulate alcohol sensitivity of the NMDA receptor. Neuropharmacology (2004) 1.00
Identification and functional analysis of a novel TRPC6 mutation associated with late onset familial focal segmental glomerulosclerosis in Chinese patients. Mutat Res (2008) 0.99
Late stage benzylic C-H fluorination with [¹⁸F]fluoride for PET imaging. J Am Chem Soc (2014) 0.98
The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients: a randomized, controlled study. Hepatology (2014) 0.98
Novel SLC12A3 mutations in Chinese patients with Gitelman's syndrome. Nephron Physiol (2008) 0.96
Improved late gadolinium enhancement MR imaging for patients with implanted cardiac devices. Radiology (2013) 0.96
Identification of a regulatory autophosphorylation site in the serine-threonine kinase RIP2. Cell Signal (2006) 0.96
AMPK activation through mitochondrial regulation results in increased substrate oxidation and improved metabolic parameters in models of diabetes. PLoS One (2013) 0.94
Liver and spleen stiffness measured by acoustic radiation force impulse elastography for noninvasive assessment of liver fibrosis and esophageal varices in patients with chronic hepatitis B. J Ultrasound Med (2012) 0.94
Proteomic investigation of 5-fluorouracil resistance in a human hepatocellular carcinoma cell line. J Cell Biochem (2012) 0.93
Fluconazole assists berberine to kill fluconazole-resistant Candida albicans. Antimicrob Agents Chemother (2013) 0.93
Quantitative proteome analysis of multidrug resistance in human ovarian cancer cell line. J Cell Biochem (2010) 0.93
Multivariate statistical analysis of clinicopathologic factors influencing survival of patients with bile duct carcinoma. World J Gastroenterol (2002) 0.92
Research resource: nuclear receptor atlas of human retinal pigment epithelial cells: potential relevance to age-related macular degeneration. Mol Endocrinol (2011) 0.91
Efficacy and safety of entecavir compared to lamivudine in nucleoside-naïve patients with chronic hepatitis B: a randomized double-blind trial in China. Hepatol Int (2007) 0.91
Virologic, serologic, and biochemical outcomes through 2 years of treatment with entecavir and lamivudine in nucleoside-naïve Chinese patients with chronic hepatitis B: a randomized, multicenter study. Hepatol Int (2008) 0.91
Therapeutic effect of autologous dendritic cell vaccine on patients with chronic hepatitis B: a clinical study. World J Gastroenterol (2005) 0.91
Estrogen receptor α mediates proliferation of breast cancer MCF-7 cells via a p21/PCNA/E2F1-dependent pathway. FEBS J (2014) 0.90
Subject-specific estimation of respiratory navigator tracking factor for free-breathing cardiovascular MR. Magn Reson Med (2011) 0.90
A label-free electrochemical immunoassay for IgG detection based on the electron transfer. Talanta (2010) 0.90
GLP-1 analogue prevents NAFLD in ApoE KO mice with diet and Acrp30 knockdown by inhibiting c-JNK. Liver Int (2013) 0.90
Expansion of circulating TFH cells and their associated molecules: involvement in the immune landscape in patients with chronic HBV infection. Virol J (2014) 0.90
A new cytotoxic lanostane-type triterpene glycoside from the sea cucumber Holothuria impatiens. Chem Biodivers (2007) 0.90
Changing spectrum of biopsy-proven primary glomerular diseases over the past 15 years: a single-center study in China. Contrib Nephrol (2013) 0.90
Smac: Its role in apoptosis induction and use in lung cancer diagnosis and treatment. Cancer Lett (2012) 0.89
Effect of all-trans retinoic acid on renal expressions of matrix metalloproteinase-2, matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in rats with glomerulosclerosis. Pediatr Nephrol (2009) 0.89
Improved therapeutic efficacy using vaccination with glioma lysate-pulsed dendritic cells combined with IP-10 in murine glioma. Vaccine (2009) 0.89
Overexpression of Smac promotes Cisplatin-induced apoptosis by activating caspase-3 and caspase-9 in lung cancer A549 cells. Cancer Biother Radiopharm (2012) 0.89
The influence of hepatitis B virus on antiviral treatment with interferon and ribavirin in Asian patients with hepatitis C virus/hepatitis B virus coinfection: a meta-analysis. Virol J (2012) 0.88
JAK3 inhibition significantly attenuates psoriasiform skin inflammation in CD18 mutant PL/J mice. J Immunol (2009) 0.88
High spatial and temporal resolution dynamic contrast-enhanced magnetic resonance angiography using compressed sensing with magnitude image subtraction. Magn Reson Med (2013) 0.88
Identification of five novel variants in the thiazide-sensitive NaCl co-transporter gene in Chinese patients with Gitelman syndrome. Nephrology (Carlton) (2009) 0.87
Propylthiouracil-associated antineutrophil cytoplasmic autoantibody-positive vasculitis: retrospective study of 19 cases. J Rheumatol (2007) 0.87
iTRAQ quantitative analysis of multidrug resistance mechanisms in human gastric cancer cells. J Biomed Biotechnol (2010) 0.87
Expression of interleukins-23 and 27 leads to successful gene therapy of hepatocellular carcinoma. Mol Immunol (2009) 0.87
Novel vaccines for the treatment of chronic HBV infection based on mycobacterial heat shock protein 70. Vaccine (2006) 0.87
Adaptive evolution of hepcidin genes in antarctic notothenioid fishes. Mol Biol Evol (2008) 0.87
Characteristics of circulating T cell receptor gamma-delta T cells from individuals chronically infected with hepatitis B virus (HBV): an association between V(delta)2 subtype and chronic HBV infection. J Infect Dis (2008) 0.86
Association between serum platelet-derived growth factor BB and degree of liver damage, fibrosis and hepatitis B e antigen (HBeAg) status in CHB patients. Hepatogastroenterology (2013) 0.86
Accelerated noncontrast-enhanced pulmonary vein MRA with distributed compressed sensing. J Magn Reson Imaging (2011) 0.86